Millennium Management’s BioLineRX BLRX Stock Holding History

Millennium Management’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-335	Closed	-$12K	–	6579
2022 Q3	$12K	Buy	+335	New	+$19.1K	﹤0.01%	6605
2021 Q3	–	Sell	-373	Closed	-$42K	–	6791
2021 Q2	$42K	Buy	+373	New	+$43.8K	﹤0.01%	6387
2018 Q1	–	Sell	-145	Closed	-$95K	–	3645
2017 Q4	$95K	Buy	+145	New	+$95.5K	﹤0.01%	3663
2016 Q3	–	Sell	-708	Closed	-$340K	–	3276
2016 Q2	$340K	Sell	708 -125	-15%	-$69.9K	﹤0.01%	2669
2016 Q1	$510K	Sell	833 -167	-17%	-$105K	﹤0.01%	2506
2015 Q4	$780K	Hold	1,000	–	–	﹤0.01%	2425
2015 Q3	$918K	Buy	1,000 +29	+3%	+$30.9K	﹤0.01%	2333
2015 Q2	$1.55M	Buy	971 +243	+33%	+$301K	﹤0.01%	2057
2015 Q1	$922K	Buy	+728	New	+$896K	﹤0.01%	2360

Other funds holding BLRX

ACM

Altium Capital Management New York $42M AUM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Millennium Management's BLRX Position: Q4 2022 in Review

Millennium Management sold out of BioLineRX (BLRX) in Q4 2022, closing a stake of 335 shares — an estimated $12K sold.

Millennium Management first reported a position in BLRX in Q1 2015 and held it in 9 quarters. The position peaked at $1.55M in Q2 2015. 18 funds tracked by Wall St. Rank hold BLRX as of Q4 2022.

Millennium Management reported no remaining BioLineRX position as of Q4 2022 after selling out during the quarter.
Millennium Management sold 335 BioLineRX shares in Q4 2022, an estimated $12K.
Millennium Management first reported a position in BioLineRX in Q1 2015 and held it in 9 quarters.
Millennium Management's BioLineRX position peaked at $1.55M in Q2 2015.
18 funds tracked by Wall St. Rank held BioLineRX as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.